Showing results (51-60 of 126) with videos related to

Sort By:
Pageof 13
American Journal of Clinical Oncology|June 11, 2003
Gemcitabine, Paclitaxel, and piritrexim: a phase I studyGlenn Liu, Howard H Bailey, Rhoda Z Arzoomanian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2005
A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancerChristopher Sweeney, Glenn Liu, Constantin Yiannoutsos, et al.
Investigational New Drugs|March 23, 2011
A phase I trial of MK-0731, a kinesin spindle protein (KSP) inhibitor, in patients with solid tumorsKyle Holen, Robert DiPaola, Glenn Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 12, 2004
A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancerGlenn Liu, David R Gandara, Primo N Lara, et al.
Journal for Immunotherapy of Cancer|March 12, 2022
Phase 2 trial of T-cell activation using MVI-816 and pembrolizumab in patients with metastatic, castration-resistant prostate cancer (mCRPC)Douglas G McNeel, Jens C Eickhoff, Ellen Wargowski, et al.
Cancer Chemotherapy and Pharmacology|January 1, 2010
Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation studyFrancisco Robert, Alan Sandler, Joan H Schiller, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 20, 2015
Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trialsKari B Wisinski, Colby A Cantu, Jens Eickhoff, et al.
Cancer Chemotherapy and Pharmacology|January 4, 2015
Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium studyJaime R Merchan, Rui Qin, Henry Pitot, et al.
Molecular Pharmaceutics|April 8, 2017
ImmunoPET Imaging of CTLA-4 Expression in Mouse Models of Non-small Cell Lung CancerEmily B Ehlerding, Christopher G England, Rebecca L Majewski, et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 3, 2014
A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancerKari B Wisinski, Wendy M Ledesma, Jill Kolesar, et al.
Pageof 13